tradingkey.logo

Stevanato Group SpA

STVN
View Detailed Chart

26.825USD

-0.105-0.39%
Market hours ETQuotes delayed by 15 min
7.32BMarket Cap
54.40P/E TTM

Stevanato Group SpA

26.825

-0.105-0.39%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.39%

5 Days

+3.81%

1 Month

+18.59%

6 Months

+30.34%

Year to Date

+23.11%

1 Year

+40.74%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
3 / 207
Overall Ranking
32 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Buy
Current Rating
29.103
Target Price
+6.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.02% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 12.27%.
Overvalued
The company’s latest PE is 54.52, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.23M shares, decreasing 21.42% quarter-over-quarter.
Held by Ron Baron
Star Investor Ron Baron holds 1.89M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Ticker SymbolSTVN
CompanyStevanato Group SpA
CEOMr. Franco Stevanato
Websitehttps://www.stevanatogroup.com/
KeyAI